Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 111 to 120 of 797

TitleReference numberPublishedLast updated
Ruxolitinib for treating polycythaemia veraTA921
Daridorexant for treating long-term insomniaTA922
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA927
Bimekizumab for treating axial spondyloarthritisTA918
Pegunigalsidase alfa for treating Fabry diseaseTA915
Bimekizumab for treating active psoriatic arthritisTA916
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiencyTA914
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathyTA913
Semaglutide for managing overweight and obesityTA875
Cipaglucosidase alfa with miglustat for treating late-onset Pompe diseaseTA912

Results per page

  1. 10
  2. 25
  3. 50
  4. All